TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21401534

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behaviour therapy (CBT) for 10 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (self-help material with e-mail contact)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behaviour therapy (CBT)
Number of subjects: 84
Study: 19642772

Group type: EXPERIMENTAL
Intervention: Narrow phonetic transcription of test consonants
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ordinal scale rating of resonance
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Perceived velopharyngeal closure (VPC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Velopharyngeal composite score (VPC-sum)
Number of subjects: 50
Study: 16730732

Group type: EXPERIMENTAL
Intervention: THD 1g daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 16009786

Group type: COMPARATOR
Intervention: ACEIs
Number of subjects: 179122

Group type: COMPARATOR
Intervention: CCBs
Number of subjects: 179122
Study: 11936564

Group type: EXPERIMENTAL
Intervention: Voriconazole 200 mg q 12 h
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Voriconazole 300 mg q 12 h
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fluconazole 400 mg OD
Number of subjects: 24
Study: 10327908

Group type: EXPERIMENTAL
Intervention: Reassurance (reiterated safety assurances)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control dial (patients were instructed on using an operative dial to reduce the concentration of CO2 in the breathing canopy)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Basic instructions (standard information)
Number of subjects: 53
Study: 7703619

Group type: EXPERIMENTAL
Intervention: Calcium absorption (net and true) measured in 18-day balances and by a two-isotope deconvolution method (fractional absorption and maximum absorption rate, MAR)
Number of subjects: 25
Study: 1668825

Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery with radiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breast-conserving surgery without radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative radiation after mastectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic adjuvant chemotherapy alone
Number of subjects: 0
Study: 7073151

Group type: EXPERIMENTAL
Intervention: Cimetidine, 300 mg four times daily for 1 day
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31362765

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) - 1-g loading dose followed by 3-g maintenance dose over 24 hours
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 12000
Study: 27038416

Group type: EXPERIMENTAL
Intervention: VL20 (20% velocity loss)
Number of subjects: 22

Group type: COMPARATOR
Intervention: VL40 (40% velocity loss)
Number of subjects: 22
Study: 26166678

Group type: EXPERIMENTAL
Intervention: Telehealth intervention offering $20 incentives for connecting to quitline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perceived incentive importance
Number of subjects: 0
Study: 24703047

Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg once weekly titrated to 50 mg at week 6
Number of subjects: 841

Group type: COMPARATOR
Intervention: Liraglutide 0.6 mg once daily titrated to 1.2 mg at week 1 and 1.8 mg at week 2
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Albiglutide
Number of subjects: 841

Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 841
Study: 22245322

Group type: COMPARATOR
Intervention: Androgen deprivation therapy (placebo group)
Number of subjects: 516
Study: 18951459

Group type: EXPERIMENTAL
Intervention: Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS) pre- and post-treatment
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Eating Disorder Examination scores
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Perfectionism
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Impulsivity
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Maximum lifetime BMI
Number of subjects: 56
Study: 17472616

Group type: EXPERIMENTAL
Intervention: Amphotericin B alone (n = 15)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Amphotericin B and 5-fluorocytosine (n = 3)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Amphotericin B and itraconazole (n = 2)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Neurosurgery (4 patients)
Number of subjects: 17
Study: 15678733

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion 15 microg kg(‐1) h(‐1)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Alfentanil infusion 60 microg kg(‐1) h(‐1)
Number of subjects: 192
Study: 12080408

Group type: EXPERIMENTAL
Intervention: Multi-micronutrient supplementation (daily tablet containing 1000 microg vitamin A)
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: Multi-helminth chemotherapy (single treatment with albendazole 600 mg and praziquantel 40 mg/kg)
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: Reduction in S. mansoni egg output
Number of subjects: 977
Study: 10335041

Group type: EXPERIMENTAL
Intervention: Asymptomatic bacteriuria (a.b.) in women with SLE
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Bacterial colonisation of nostrils and pharynx in SLE patients with a.b.
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Clinical observation of patients with a.b.
Number of subjects: 85
Study: 7807254

Group type: EXPERIMENTAL
Intervention: Traditional method of instruction
Number of subjects: 70

Group type: COMPARATOR
Intervention: Computer method of instruction
Number of subjects: 70
Study: 2762760

Group type: EXPERIMENTAL
Intervention: Screening with Hemoccult‐II
Number of subjects: 60938
Study: 824884

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29931108

Group type: EXPERIMENTAL
Intervention: Nutrition-focused MNCH program
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard MNCH program
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Husbands' behavioral determinants and support
Number of subjects: 1000
Study: 26581683

Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea extract (GTE) 1315 mg total catechins/d
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: COMT high-activity (G/G) genotype
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: COMT low-activity (A/A) genotype
Number of subjects: 237
Study: 24533491

Group type: EXPERIMENTAL
Intervention: Static Dynamic Stretching (SDS)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Active Dynamic Stretching (ADS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no dynamic stretching)
Number of subjects: 37
Study: 22497967

Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin (G-GR) 3000mg once daily (G-GR-QD)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin (G-GR) divided dose (G-GR-DD, 1200mg AM/1800mg PM)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 20941926

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 18539989

Group type: EXPERIMENTAL
Intervention: Melatonin 5 or 2.5 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 16105600

Group type: EXPERIMENTAL
Intervention: Advanced surface ablation
Number of subjects: 28
Study: 12917299

Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin therapy (target INR of 1.5 to 1.9)
Number of subjects: 738

Group type: COMPARATOR
Intervention: Conventional-intensity warfarin therapy (target INR of 2.0 to 3.0)
Number of subjects: 738
Study: 10622270

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Iloprost treatment (0.5-2 ng/Kg/min)
Number of subjects: 20
Study: 8556228

Group type: COMPARATOR
Intervention: UFT therapy alone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: UFT therapy in combination with Bestatin
Number of subjects: 45
Study: 1951565

Group type: EXPERIMENTAL
Intervention: Prophylactic amnioinfusion
Number of subjects: 305

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 305
Study: 7034155

Group type: EXPERIMENTAL
Intervention: Cimetidine, 1 g/day
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Antacid/anticholinergic (10 ml of antacid suspension and 0.6 mg L-hyoscyamine twice a day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Antacid/anticholinergic
Number of subjects: 72
Study: 31729566

Group type: EXPERIMENTAL
Intervention: 6-month exercise program of supervised indoor and outdoor group sessions in addition to usual nutritional care (n = 41)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual nutritional care group receiving dietary and physical activity counseling (n = 19)
Number of subjects: 60
Study: 29074061

Group type: EXPERIMENTAL
Intervention: Docetaxel (first-line)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Docetaxel (first- or second-line)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Abiraterone or Enzalutamide
Number of subjects: 245
Study: 26716863

Group type: EXPERIMENTAL
Intervention: NAVA with sevoflurane
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: NAVA with propofol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: NAVA with sevoflurane and remifentanil
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: NAVA with propofol and remifentanil
Number of subjects: 9
Study: 24690159

Group type: EXPERIMENTAL
Intervention: Whole grain and legume group (n=92)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Refined rice group (n=93)
Number of subjects: 185
Study: 22278643

Group type: EXPERIMENTAL
Intervention: Healing Touch (HT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 41
Study: 20372083

Group type: EXPERIMENTAL
Intervention: Intradermal influenza vaccination
Number of subjects: 5305

Group type: COMPARATOR
Intervention: Intramuscular vaccination
Number of subjects: 5305

Group type: EXPERIMENTAL
Intervention: Intradermal microinjection system
Number of subjects: 5305

Group type: COMPARATOR
Intervention: Conventional intramuscular syringe
Number of subjects: 5305
Study: 18620598

Group type: EXPERIMENTAL
Intervention: Standard of care and Procalcitonin guided diagnostics and treatment of infection
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1000
Study: 16093865

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40 kDa) plus ribavirin for 48 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40 kDa) plus ribavirin for 72 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose induction regimen with peginterferon alfa-2a (40 kDa) 360 mug once-weekly for 12 weeks followed by 60 weeks of peginterferon alfa-2a (40 kDa) 180 mug once weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose induction regimen with peginterferon alfa-2a (40 kDa) 360 mug once-weekly for 12 weeks followed by 36 weeks of peginterferon alfa-2a (40 kDa) 180 mug once weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40 kDa) plus ribavirin
Number of subjects: 0
Study: 12520671

Group type: EXPERIMENTAL
Intervention: Ventricular Rate Stabilization (VRS) On
Number of subjects: 309

Group type: COMPARATOR
Intervention: Ventricular Rate Stabilization (VRS) Off
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: VRS On
Number of subjects: 309

Group type: COMPARATOR
Intervention: VRS Off
Number of subjects: 309
Study: 11042832

Group type: EXPERIMENTAL
Intervention: 1-hr or 3-hr sperm-oocyte incubation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard overnight gamete co-incubation
Number of subjects: 23
Study: 9104690

Group type: EXPERIMENTAL
Intervention: Bright morning light (> 2,500 lux)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bright evening light (PM; 19:00 to 21:00 h)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Dim red evening light (RED; < 10 lux)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Light therapy in NC subjects
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Comparison of AM, PM, and RED light
Number of subjects: 32
Study: 1343921

Group type: EXPERIMENTAL
Intervention: Oxamniquine, single dosage of 15 mg/kg for adults and 20 mg/kg for children divided in two doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Praziquantel, single dose of 60 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Praziquantel, sequential doses of 60 mg/kg during 3 days or 30 mg/kg for 6 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both drugs (Oxamniquine and Praziquantel)
Number of subjects: 0
Study: 3547254

Group type: EXPERIMENTAL
Intervention: Fluoromethalone 0.1% suspension (FML)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate 0.1% (Eumovate)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate 0.1% (Betnesol)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Higher penetration steroids
Number of subjects: 50
Study: 29409260

Group type: EXPERIMENTAL
Intervention: MTH preserving technique
Number of subjects: 23

Group type: COMPARATOR
Intervention: MTH resecting technique
Number of subjects: 23
Study: 28717985

Group type: EXPERIMENTAL
Intervention: Peer teaching (PT)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Peer teaching using Peyton's four-step approach (PPT)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Team based learning (TBL)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Video-based learning (VBL)
Number of subjects: 79
Study: 26920441

Group type: EXPERIMENTAL
Intervention: Sitting with 3 min bouts of light-intensity walking every 30 min
Number of subjects: 19

Group type: COMPARATOR
Intervention: Uninterrupted sitting (sedentary condition)
Number of subjects: 19
Study: 25589677

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 1050
Study: 23099447

Group type: EXPERIMENTAL
Intervention: Fluoxetine monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium monotherapy
Number of subjects: 0
Study: 21180354

Group type: EXPERIMENTAL
Intervention: Male and female perfumes as nonconscious stimulation during visual assessments
Number of subjects: 0
Study: 18377975

Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loading dose, 10 mg daily maintenance)
Number of subjects: 12844

Group type: COMPARATOR
Intervention: Clopidogrel (300 mg loading dose, 75 mg daily maintenance)
Number of subjects: 12844
Study: 16775579

Group type: EXPERIMENTAL
Intervention: High soy diet (two daily soy servings)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low soy diet (maintaining usual diet)
Number of subjects: 24
Study: 14718746

Group type: EXPERIMENTAL
Intervention: Margarine containing medium-chain triacylglycerols (MCT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Long-chain triacylglycerols (LCT)
Number of subjects: 73
Study: 10976612

Group type: EXPERIMENTAL
Intervention: Pretest assessment with interactive interventions (skills or demonstration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No pretest assessment with interactive interventions (skills or demonstration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pamphlet review only (no pretest)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pretest assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactive interventions (skills or demonstration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactive intervention
Number of subjects: 0
Study: 17429240

Group type: EXPERIMENTAL
Intervention: Fiberoptic phototherapy (n=16)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Conventional daylight phototherapy (n=15)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Combination phototherapy (n=15)
Number of subjects: 46
Study: 1415973

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 24
Study: 31734218

Group type: EXPERIMENTAL
Intervention: Audio-visual practice group (N = 177)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Audio-visual group (N = 157)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Control group (N = 114)
Number of subjects: 641
Study: 31004470

Group type: EXPERIMENTAL
Intervention: Clazosentan (15 mg/hour for 3 hours) after rifampin (600 mg/100 mL in 30 minutes)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Clazosentan (15 mg/hour for 3 hours) after placebo
Number of subjects: 14
Study: 28872919

Group type: EXPERIMENTAL
Intervention: Edaravone
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study: 25972279

Group type: EXPERIMENTAL
Intervention: ECO intervention (blended eHealth module embedded in Collaborative Occupational health care)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: ECO intervention
Number of subjects: 220
Study: 24308025

Group type: EXPERIMENTAL
Intervention: Very low-intensity transcranial magnetic stimulation (8 Hz pulsed magnetic fields)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham group (no stimulation)
Number of subjects: 54
Study: 21169619

Group type: EXPERIMENTAL
Intervention: Revised version of the website
Number of subjects: 77

Group type: COMPARATOR
Intervention: Original version of the website
Number of subjects: 77
Study: 19816871

Group type: EXPERIMENTAL
Intervention: High bolus dose tirofiban (25 microg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (saline bolus and infusion)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High bolus dose tirofiban (25 microg/kg) in patients with diabetes mellitus
Number of subjects: 100
Study: 17234504

Group type: EXPERIMENTAL
Intervention: BCAA-enriched nutrient mixture
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ordinary food (rice ball or bread)
Number of subjects: 48
Study: 15133532

Group type: EXPERIMENTAL
Intervention: RPR749 (200 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 12455284

Group type: EXPERIMENTAL
Intervention: Pelvic floor rehabilitation
Number of subjects: 8
Study: 9845975

Group type: EXPERIMENTAL
Intervention: Modeling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modeling with retrieval cues
Number of subjects: 0
Study: 7814131

Group type: EXPERIMENTAL
Intervention: Injected thermoplasticized gutta‐percha
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lateral condensation technique
Number of subjects: 30
Study: 2680677

Group type: EXPERIMENTAL
Intervention: 12 mg/day piretanide
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 6 mg/day piretanide
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 2.5 mg/day bendroflumethiazide
Number of subjects: 76
Study: 1127136

Group type: EXPERIMENTAL
Intervention: naproxen (500 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 31056442

Group type: EXPERIMENTAL
Intervention: VR‐THA simulation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study: 28757438

Group type: EXPERIMENTAL
Intervention: Fascial Closure Device (FCD)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Traditional Fascial Closure (TFC)
Number of subjects: 67
Study: 25647122

Group type: EXPERIMENTAL
Intervention: Simulation-based mastery learning session
Number of subjects: 42
Study: 24947791

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL) at doses ranging from 5.1 to 74.1 mU/min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Insulin glargine at doses of 20 or 30 mU/m(2)/min
Number of subjects: 8
Study: 22259793

Group type: EXPERIMENTAL
Intervention: Panavia F 2.0
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rely X Unicem
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Thermocycled specimens
Number of subjects: 32

Group type: COMPARATOR
Intervention: Natural teeth (control group)
Number of subjects: 32
Study: 19321988

Group type: EXPERIMENTAL
Intervention: Educational intervention group A (oral health instructions + extra reminders)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Educational intervention group B (oral health instructions)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 242
Study: 17705104

Group type: EXPERIMENTAL
Intervention: INF-RIBA-AMA
Number of subjects: 30

Group type: COMPARATOR
Intervention: INF-RIBA
Number of subjects: 30
Study: 15377966

Group type: EXPERIMENTAL
Intervention: ACL-reconstructed group
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 11569479

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Recormon), 20 IE/kg subcutaneously three times/week for 4 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (no erythropoietin treatment)
Number of subjects: 13
Study: 9631134

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (500 mg twice daily)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 7889226

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2845043

Group type: EXPERIMENTAL
Intervention: DMSA 350 mg/m2/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DMSA 700 mg/m2/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DMSA 1050 mg/m2/day
Number of subjects: 21

Group type: COMPARATOR
Intervention: CaNa2EDTA 1000 mg/m2/day
Number of subjects: 21
Study: 31415213

Group type: EXPERIMENTAL
Intervention: Intralesional injection of vitamin D3 (0.3 ml, 100,000 IU (2.5 mg/ml))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intralesional injection of 2% zinc sulfate
Number of subjects: 40
Study: 31823141

Group type: EXPERIMENTAL
Intervention: MTX-hold group (4-week discontinuation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MTX-continue group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-week MTX-hold group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-week MTX-hold group
Number of subjects: 0
Study: 30185421

Group type: EXPERIMENTAL
Intervention: Combinatorial proteomic biomarker assay (CPBA), Videssa Breast
Number of subjects: 663